10-Q: Assertio Holdings Reports Wider Loss Amid Divestitures

Assertio Holdings, Inc. reported a significantly wider net loss for the second quarter and first half of 2025, driven by strategic divestitures and ongoing legal expenses, despite some product sales growth.

Summary

• Net loss for the three months ended June 30, 2025, widened to $16.352 million, compared to a net loss of $3.674 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, increased to $29.893 million, from $8.184 million in the prior year period.
• Total revenues for the three months ended June 30, 2025, decreased to $29.222 million from $31.126 million in 2024.
• Total revenues for the six months ended June 30, 2025, decreased to $55.712 million from $63.574 million in 2024.
• The company completed the divestiture of Assertio Therapeutics on May 9, 2025, resulting in an $8.174 million net loss on the transaction.
• Commercialization of Otrexup ceased in July 2025, incurring $3.8 million in related expenses during the three and six months ended June 30, 2025.
• ROLVEDON net product sales increased to $16.128 million for the three months ended June 30, 2025, up from $15.144 million in the prior year, primarily due to higher volume and a $5.4 million adjustment of a prior period returns reserve.
• INDOCIN net product sales significantly decreased to $3.033 million for the three months ended June 30, 2025, from $6.913 million in 2024, primarily due to lower volume and pricing from generic competition.
• Cash and cash equivalents decreased to $47.086 million as of June 30, 2025, from $50.588 million at December 31, 2024.
• Net cash provided by operating activities for the six months ended June 30, 2025, was $6.553 million, a decrease from $14.895 million in the prior year period.
• The company settled the Luo v. Spectrum Pharmaceuticals, Inc., et al. class action for $16.0 million, with $2.7 million paid by the company and $13.3 million covered by insurance, settled in July 2025.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to significant widening of net losses, declining overall revenues, and a substantial decrease in cash generated from operations. While some products like ROLVEDON and Sympazan show sales growth, this is overshadowed by the sharp decline in INDOCIN sales due to generic competition and one-time losses from divestitures and decommercialization. The company faces multiple ongoing legal challenges and a Nasdaq compliance issue, indicating significant operational and financial headwinds. The liquidity position, while deemed sufficient for 12 months, is fragile given the cash burn and potential need for additional capital.

Positives

• ROLVEDON net product sales increased by $1.0 million for the three months ended June 30, 2025, driven by higher volume and a favorable prior period returns reserve adjustment.
• Sympazan net product sales increased by $0.6 million for the three months ended June 30, 2025, due to higher volume and favorable payor mix.
• The divestiture of Assertio Therapeutics eliminated the company's exposure to opioid-related litigation.
• The company was in compliance with its covenants for the 6.5% Convertible Senior Notes due 2027 as of June 30, 2025.
• Successfully settled the Glumetza antitrust claims and Qui Tam litigation, resolving significant legal exposures.

Negatives

• Net loss significantly widened for both the three and six months ended June 30, 2025, compared to the prior year periods.
• Total revenues decreased for both the three and six months ended June 30, 2025, compared to the prior year periods.
• INDOCIN net product sales experienced a substantial decline due to generic competition.
• The divestiture of Assertio Therapeutics resulted in an $8.174 million net loss on the transaction.
• Ceasing commercialization of Otrexup incurred $3.8 million in one-time expenses.
• Net cash provided by operating activities decreased significantly from $14.895 million in the first six months of 2024 to $6.553 million in the first six months of 2025.
• The company's market capitalization was below the book value of its equity, indicating potential impairment risk for long-lived assets.
• The SPRIX asset group's estimated undiscounted cash flows exceeded its carrying value by only approximately 20%, indicating sensitivity to unfavorable changes and potential future impairment charges.
• The company received a deficiency notification on January 22, 2025, regarding non-compliance with The Nasdaq Capital Market's minimum closing bid requirement of at least $1.00 per share.

Risks

• Ability to grow sales and achieve commercial success and market acceptance of ROLVEDON and other products, including payor coverage.
• Entry and sales of generics for existing products, particularly the ongoing impact of generic indomethacin suppositories and new/expected future generic entrants.
• Negative impact on average sales price for ROLVEDON due to increased discounts, chargebacks, rebates, and competition.
• Delays, challenges, expenses, and unexpected liabilities associated with integrating and operating newly-acquired products.
• Ability to retain executive leadership and key employees.
• Reliance on single-source suppliers for manufacturing and maintaining the supply chain.
• Outcome and costs of pending and potential future disputes, litigation, or government investigations, including multiple ongoing securities class actions and derivative lawsuits.
• Potential expenses, including termination expenses, if a decision is made to cease development of Spectrum's de-prioritized development asset poziotinib.
• Ability to generate sufficient cash flow from business to fund operations and make payments on indebtedness.
• Ability to raise additional capital or refinance debt if cash needs exceed current expectations.
• Potential impacts of adverse business and economic conditions, including inflationary pressures, economic slowdown, or high interest rates.
• Potential impacts of changes to U.S. and international trade policies, including tariffs.
• Risk of cybersecurity breaches impacting compliance, intellectual property, and operations.
• Failure to regain and maintain compliance with The Nasdaq Capital Market's minimum closing bid requirement of at least $1.00 per share.

Future Outlook

The company expects the average sales price for ROLVEDON to be negatively impacted in the remainder of 2025 due to increased discounts, chargebacks, rebates, and competition. INDOCIN net product sales are expected to continue to be unfavorably impacted by increasing generic competition. Pricing for all products is expected to be affected by higher discounts, chargebacks, and rebates. Cost of sales, as a percentage of sales, is expected to be negatively affected by changes in product volume and mix. The company believes existing cash and cash equivalents and short-term investments of $98.2 million at June 30, 2025, will be sufficient to fund operations and debt payments for the next 12 months, but cash needs may vary materially due to various factors including litigation expenses, working capital fluctuations, and potential acquisitions. Ongoing legal expenses and potential settlements are expected to be a significant usage of cash in the remainder of 2025. The company is evaluating the impact of recent tax law changes (H.R. 1) on its tax provision and financial statements.

Management Comments

• We believe that ROLVEDON's profile provides opportunities in both hospitals and community oncology clinics.
• We are working to identify further opportunities for ROLVEDON.
• We expect that the average sales price for ROLVEDON, which is used to set pricing for a significant portion of our net product sales, will be negatively impacted due to increased discounts, chargebacks, rebates given to our customers and increased competition.
• We expect INDOCIN net product sales to continue to be impacted unfavorably by increasing competition as a result of existing generic entrants, new and expected future generic entrants, including two new generic entrants in 2025, and other competitive products.
• Due to the competitive markets in which our products compete, we expect the pricing of all of our products to be impacted by higher discounts, chargebacks, and rebates in the remainder of 2025 as compared to 2024.
• We expect Cost of sales, as a percentage of sales, to continue to be negatively affected by changes in product volume and mix as compared to 2024.
• We expect expenses associated with the ROLVEDON pediatric safety clinical trial to be significantly reduced in future periods.
• We believe that our existing cash and cash equivalents and short-term investments, which totaled $98.2 million at June 30, 2025, will be sufficient to fund our operations and make the required payments under our debt agreements due for the next 12 months from the date of this filing.
• We expect that ongoing legal expenses will, and any settlements that we are able to negotiate may, continue to be a significant usage of cash in the remainder of 2025.
• We may be required to raise additional capital if our cash needs vary significantly from current expectations.

Industry Context

The pharmaceutical industry is characterized by intense competition, pricing pressures, and the constant threat of generic entry. Assertio Holdings operates in this environment, focusing on oncology, neurology, and pain management. The company's strategy of acquiring and licensing approved products, such as ROLVEDON, is common in the industry for portfolio expansion. However, the significant decline in INDOCIN sales due to generic competition highlights a pervasive industry challenge. The ongoing legal proceedings, particularly securities class actions, reflect the high scrutiny and regulatory risks inherent in the pharmaceutical sector. The company's efforts to streamline operations through divestitures and decommercialization are indicative of a broader industry trend towards optimizing portfolios and reducing non-core assets to improve efficiency and focus on high-potential products like ROLVEDON.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Shapiro v. Assertio Holdings, Inc., et al.: Putative securities class action alleging false/misleading statements regarding INDOCIN sales and Spectrum Merger impact. Company intends to vigorously defend.
• In re Assertio Holdings, Inc. Derivative Litigation: Consolidated stockholder derivative actions alleging breach of fiduciary duties and gross mismanagement, stayed pending the Shapiro class action.
• Jung v. Lebel, et al. and Jung v. Turgeon, et al.: Stockholder derivative complaints filed in Delaware Chancery Court, largely duplicative of other class actions, alleging wrongful refusal of demands. Company and Spectrum moved to dismiss.
• Luo v. Spectrum Pharmaceuticals, Inc., et al.: Putative securities class action settled in principle for $16.0 million, with the company responsible for $2.7 million and insurance covering $13.3 million. Settlement funded in July 2025, final approval hearing October 20, 2025.
• Christiansen v. Spectrum Pharmaceuticals, Inc. et al.: Securities class action alleging false/misleading statements about poziotinib. Lead plaintiff disqualified, new lead plaintiff process initiated, case remains stayed. Company intends to vigorously defend.
• Enyart v. Assertio Holdings, Inc., et. al.: Putative securities class action alleging misrepresentations/omissions in the registration statement for Assertio shares issued in the Spectrum Merger. Complaint dismissed with leave to re-plead, amended complaint filed July 18, 2025. Company intends to vigorously defend.
• Assertio Therapeutics Opioid Litigation: The company is no longer a defendant in any opioid-related litigation following the divestiture of Assertio Therapeutics on May 9, 2025.
• Glumetza Antitrust Litigation: Claims by Humana Inc. and Health Care Service Corporation settled in Q3 2024 (confidential terms) and paid in full during Q2 2025. Cases dismissed in June 2025.
• Qui Tam Litigation: Settled with DOJ and relators on May 8, 2025, for $3.6 million, which was paid on the same date.

Related Party Transactions

• Contingent consideration obligation to an affiliate of CR Group L.P. for future royalties based on annual INDOCIN product net sales over $20.0 million at a 20% royalty through January 2029. Fair value determined to be $0.7 million as of June 30, 2025.

Stakeholder Impact

• Shareholders: Face increased net losses, decreased shareholder equity, potential dilution from convertible notes, and uncertainty from ongoing litigation and Nasdaq listing compliance issues.
• Employees: Affected by past restructuring plans (Spectrum Reorganization Plan) involving workforce reductions and ongoing severance payments.
• Customers: Continued access to key products like ROLVEDON, Sympazan, INDOCIN, SPRIX, and CAMBIA, but Otrexup commercialization has ceased. May experience pricing impacts due to higher discounts and rebates.
• Suppliers/Manufacturers: Hanmi supply commitment for ROLVEDON met. Antares Pharma, Inc. faces potential default/litigation regarding the Otrexup supply agreement due to decommercialization.
• Creditors: The company remains in compliance with covenants for its 2027 Convertible Notes, but ongoing cash usage for legal expenses and potential need for additional capital could impact future creditworthiness.

Next Steps

• Present an abstract of real-world evidence for Sympazan at the American Neurological Association Annual Meeting in September.
• Continue efforts to grow sales and market acceptance of ROLVEDON, including potential inclusion of same-day dosing trial data in NCCN guidelines.
• Complete all severance and benefits cash payments to the former President and Chief Executive Officer by the end of the third quarter of 2025.
• Complete all cash payments associated with restructuring undertaken in the first quarter of 2025 by the end of the third quarter of 2025.
• Complete all cash payments under the Spectrum Reorganization Plan by the end of 2025.
• Court hearing for final approval of the Luo case settlement scheduled for October 20, 2025.
• Applications for substitute lead plaintiff in the Christiansen case due by September 24, 2025.
• Respond to the amended complaint filed by Enyart in the securities class action.

Key Dates

Recommendation

The filing reveals a deteriorating financial position with significantly widened net losses and declining overall revenues. While strategic divestitures aim to streamline operations, they have incurred substantial one-time losses. Cash flow from operations has decreased, indicating a continued burn. The company faces multiple complex and costly legal proceedings, including securities class actions, which pose significant financial and reputational risks. Furthermore, the Nasdaq minimum bid price deficiency adds to the uncertainty, potentially leading to delisting. The threat of generic competition to key products like INDOCIN and expected pricing pressures on ROLVEDON suggest ongoing revenue challenges. Given the severe financial headwinds, high litigation exposure, and market compliance issues, the stock presents a high-risk profile with limited near-term upside, warranting a strong sell recommendation for investors.

Keywords

Pharmaceuticals, Oncology, Neurology, Pain Management, ROLVEDON, Sympazan, INDOCIN, SPRIX, SEC Filing, 10-Q, Financial Results, Litigation, Divestiture, Generic Competition, Nasdaq Compliance